Effects of tolcapone on working memory and brain activity in abstinent smokers: A proof-of-concept study by Ashare Rebecca L, Wileyto E Paul, Ruparel Kosha, Goelz Patricia M, Hopson Ryan D, Valdez Jeffrey N, Gur Ruben C, Loughead James, Lerman Caryn in Drug and alcohol dependence (2013). PubMed


Dopamine levels in the prefrontal cortex (PFC) are thought to play an important role in cognitive function and nicotine dependence. The catechol-O-methyltransferase (COMT) inhibitor tolcapone, an FDA-approved treatment for Parkinson's disease, increases prefrontal dopamine levels, with cognitive benefits that may vary by COMT genotype. We tested whether tolcapone alters working memory-related brain activity and performance in abstinent smokers.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Dosing Information

No dosing information annotated.